Patents by Inventor Alan S. WAYNE

Alan S. WAYNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160243192
    Abstract: Described herein are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof by administering an effective amount of a composition comprising exosomes that comprise Fc receptors. In some embodiments, the exosomes in the pharmaceutical compositions described herein comprise Fc receptors including Fcgamma1 (CD64), Fcgamma2 (CD32), Fcgamma3 (CD16) or combinations thereof.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 25, 2016
    Applicant: Children's Hospital Los Angeles
    Inventors: Robert C. SEEGER, Muller FABBRI, Ambrose JONG, Alan S. WAYNE
  • Publication number: 20150218286
    Abstract: The present invention provides methods for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients using an anti-CD22 immunotoxin. The methods disclosed comprise administering to a pediatric patient in need of that treatment an effective dose of a recombinant immunotoxin comprising a variable light (VL) chain linked to a variable heavy (VH) which is genetically fused to a therapeutic moiety comprising a Pseudomonas exotoxin A PE38 fragment. The recombinant immunotoxin specifically binds CD22 thereby inhibiting the growth of CD22-expressing (CD22+) ALL cancer cells.
    Type: Application
    Filed: November 25, 2014
    Publication date: August 6, 2015
    Inventors: Alan S. WAYNE, Ira Pastan
  • Publication number: 20120177567
    Abstract: The present invention provides methods for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients using an anti-CD22 immunotoxin. The methods disclosed comprise administering to a pediatric patient in need of that treatment an effective dose of a recombinant immunotoxin comprising a variable light (VL) chain linked to a variable heavy (VH) which is genetically fused to a therapeutic moiety comprising a Pseudomonas exotoxin A PE38 fragment. The recombinant immunotoxin specifically binds CD22 thereby inhibiting the growth of CD22-expressing (CD22+) ALL cancer cells.
    Type: Application
    Filed: August 11, 2011
    Publication date: July 12, 2012
    Applicants: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MEDIMMUNE, LLC
    Inventors: Alan S. WAYNE, Ira Pastan, Karen Kaucic, Robert Lechleider